Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Molecular pathogenesis of chronic myeloid leukemia

Molecular pathogenesis of chronic myeloid leukemia Chronic myeloid leukemia (CML) is a paradigm for effective targeted therapy and is characterized by the hallmark BCR-ABL1 fusion. Although survival of affected patients has dramatically increased with the introduction of tyrosine kinase inhibitor therapy, kinase-dependent and -independent resistance mechanisms remain a problem and therefore new clinical strategies based on our growing knowledge of cellular processes are required. New diagnostic opportunities support this task and will change disease management in the future. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png memo - Magazine of European Medical Oncology Springer Journals

Molecular pathogenesis of chronic myeloid leukemia

Loading next page...
 
/lp/springer-journals/molecular-pathogenesis-of-chronic-myeloid-leukemia-C4JNMyS7Ay
Publisher
Springer Journals
Copyright
Copyright © 2016 by Springer-Verlag Wien
Subject
Medicine & Public Health; Oncology; Medicine/Public Health, general
ISSN
1865-5041
eISSN
1865-5076
DOI
10.1007/s12254-016-0294-0
Publisher site
See Article on Publisher Site

Abstract

Chronic myeloid leukemia (CML) is a paradigm for effective targeted therapy and is characterized by the hallmark BCR-ABL1 fusion. Although survival of affected patients has dramatically increased with the introduction of tyrosine kinase inhibitor therapy, kinase-dependent and -independent resistance mechanisms remain a problem and therefore new clinical strategies based on our growing knowledge of cellular processes are required. New diagnostic opportunities support this task and will change disease management in the future.

Journal

memo - Magazine of European Medical OncologySpringer Journals

Published: Nov 10, 2016

References